predominantli
express
basolater
membran
hepatocyt
physiolog
condit
mediat
hepat
uptak
mani
clinic
import
drug
eg
lipidlow
statin
antibiot
anticanc
drug
drug
potent
oatp
inhibitor
eg
cyclosporin
may
caus
clinic
signific
drugdrug
interact
ddi
prescrib
oatp
substrat
statin
exampl
increas
system
exposur
statin
statinrel
myopathi
even
rhabdomyolysi
observ
drug
coadminist
oatp
inhibitor
overlap
substrat
specif
substrat
statin
bromosulphophthalein
transport
howev
substrat
endogen
compound
octapeptid
cholecystokinin
character
lysosom
pathway
ubiquitinproteasom
system
up
major
mechan
protein
degrad
intracellularli
previous
report
lysosom
pathway
involv
degrad
treatment
lysosom
inhibitor
chloroquin
decreas
transport
vitro
associ
increas
statinrel
myopathi
patient
treat
concurr
chloroquin
metabol
stabl
statin
addit
degrad
lysosom
membran
protein
includ
membranetransport
protein
degrad
via
ubiquitinproteasom
system
degrad
protein
via
ubiquitin
proteasom
system
involv
tag
protein
attach
multipl
ubiquitin
molecul
mediat
recognit
subsequ
degrad
proteasom
inhibit
proteasom
activ
proteasom
inhibitor
associ
alter
transport
protein
function
current
ubiquitin
effect
proteasom
inhibit
transport
function
elucid
proteasom
inhibitor
bortezomib
current
frontlin
therapi
treatment
newli
diagnos
multipl
myeloma
patient
patient
mantl
cell
lymphoma
receiv
least
one
prior
therapi
interact
bortezomib
metabol
enzym
character
past
decad
bortezomib
substrat
sever
cytochrom
isoenzym
mildli
inhibit
therefor
major
metabolismmedi
ddi
anticip
statin
wide
prescrib
treatment
hypercholesterolemia
hypertens
also
report
benefici
effect
cancer
includ
multipl
myeloma
sinc
elev
system
exposur
statin
due
ddi
may
caus
sever
side
effect
determin
ddi
potenti
myopathi
risk
associ
bortezomib
upon
concurr
administr
oatp
substrat
statin
signific
clinic
relev
date
potenti
bortezomib
caus
oatpmedi
ddi
assess
current
studi
design
determin
ubiquitin
investig
effect
proteasom
inhibitor
transport
human
embryon
kidney
hek
stabl
cell
line
physiolog
relev
human
sandwichcultur
hepatocyt
sch
model
use
studi
unlabel
estradiol
igep
hank
balanc
salt
solut
hbss
dexamethason
dimethyl
sulfoxid
dmso
triton
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
fb
nethylmaleimid
trypsinedta
solut
antibiot
antimycot
solut
dulbecco
phosphatebuff
salin
dpb
bromosulfophthalein
bsp
bovin
serum
albumin
bsa
epoxomicin
purchas
sigmaaldrich
st
loui
mo
usa
carfilzomib
obtain
lc
laboratori
woburn
usa
insulin
minimum
essenti
medium
mem
nonessenti
amino
acid
neaa
lglutamin
geneticin
penicillinstreptomycin
procur
life
technolog
grand
island
ny
usa
matrigel
insulintransferrinselenium
premix
purchas
bd
bioscienc
bedford
polyllysin
obtain
trevigen
inc
gaithersburg
md
usa
complet
proteas
inhibitor
cocktail
tablet
purchas
roch
diagnost
indianapoli
usa
bortezomib
procur
toronto
research
chemic
toronto
ontario
canada
purchas
emd
millipor
billerica
usa
specif
activ
cimmol
specif
activ
cimmol
obtain
perkin
elmer
life
scienc
waltham
usa
pitavastatin
specif
activ
cimmol
unlabel
pitavastatin
purchas
american
radiolabel
chemic
st
loui
mo
usa
biosaf
ii
liquid
scintil
mixtur
obtain
research
product
intern
mt
prospect
il
reagent
procur
vwr
intern
radnor
pa
usa
plasmid
vector
express
flagtag
describ
previous
plasmid
haub
obtain
dr
shunb
ning
plasmid
confirm
sequenc
cell
seed
densiti
x
cell
per
well
cultur
plate
twentyfour
hour
seed
cell
transfect
haub
empti
vector
control
either
alon
combin
use
lipofectamin
invitrogen
life
technolog
per
manufactur
instruct
fortyeight
hour
posttransfect
cell
wash
pb
buffer
subject
subsequ
immunoprecipit
immunoblot
human
embryon
kidney
hek
stabl
cell
line
overexpress
provid
dr
dietrich
keppler
stabl
cell
line
overexpress
flagtag
describ
previous
stabl
cell
line
overexpress
flagmyctag
establish
transfect
plasmid
vector
describ
previous
cell
follow
select
geneticin
stabl
cell
line
maintain
dmem
medium
contain
fb
antibiot
antimycot
solut
geneticin
cultur
humidifi
atmospher
human
hepatocyt
purchas
triangl
research
lab
llc
research
triangl
park
nc
usa
life
technolog
carlsbad
ca
usa
demograph
human
hepatocyt
donor
list
tabl
human
sch
cultur
describ
previous
brief
cell
seed
cultur
plate
densiti
cell
per
well
day
zero
phenol
redfre
dmem
contain
vv
fb
vv
mem
neaa
mm
lglutamin
penicillinstreptomycin
uml
dexamethason
insulin
six
hour
seed
cell
attach
plate
cell
overlaid
final
concentr
mgml
phenol
redfre
dmem
supplement
mm
lglutamin
vv
mem
neaa
unitsml
penicillinstreptomycin
solut
dexamethason
vv
premix
experi
conduct
day
one
h
cultur
immunoprecipit
immunoblot
assay
conduct
similar
publish
previous
brief
whole
cell
lysat
wcl
prepar
lyse
cell
lysi
buffer
contain
mm
trishcl
ph
mm
nacl
mm
edta
nadeoxychol
completetm
proteas
inhibitor
cocktail
roch
diagnost
usa
indianapoli
usa
protein
concentr
lysat
determin
use
bca
assay
pierc
chemic
rockford
il
usa
whole
cell
lysat
mg
lysi
buffer
first
preclear
incub
normal
mous
igg
santa
cruz
dalla
tx
usa
protein
ag
plusagaros
santa
cruz
dalla
tx
usa
min
gentl
rotat
centrifug
supernat
incub
mous
monoclon
antiflag
sigma
st
loui
mo
usa
mous
monoclon
antiha
santa
cruz
sc
antibodi
h
immunocomplex
adsorb
protein
agagaros
bead
overnight
wash
four
time
lysi
buffer
immunocomplex
elut
protein
agagaros
bead
boil
laemmli
buffer
min
order
avoid
protein
aggreg
whole
cell
lysat
immunoblot
boil
unless
state
otherwis
whole
cell
lysat
elut
immunocomplex
resolv
sodium
polyacrylamid
gel
electrophoresi
sdspage
transfer
protein
membran
blot
block
milk
trisbuff
salin
tween
tbst
incub
room
temperatur
rt
h
overnight
follow
antibodi
flag
monoclon
antibodi
sigma
st
loui
mo
usa
ha
dilut
santa
cruz
dalla
tx
usa
usa
monoclon
antibodi
dilut
sigma
st
loui
mo
usa
customgener
rabbit
polyclon
antibodi
mous
monoclon
ubiquitin
antibodi
clone
santa
cruz
dalla
tx
usa
rins
tbst
blot
incub
appropri
horseradish
peroxidaseconjug
secondari
antibodi
santa
cruz
dalla
texa
h
room
temperatur
incub
supersign
west
dura
chemiluminesc
substrat
pierc
rockford
il
imag
captur
use
biorad
chemidoc
xr
imag
system
biorad
laboratori
hercul
ca
immunoblot
imag
shown
current
manuscript
captur
satur
adjust
contrast
bright
linear
rang
optim
visual
densitometri
analys
perform
use
imag
lab
softwar
biorad
laboratori
hercul
ca
cell
seed
densiti
x
cellswel
cultur
plate
cultur
confluenc
stabl
cell
line
human
sch
either
preincub
cultur
medium
contain
test
compound
vehicl
control
preincub
begin
transport
studi
remain
untreat
coincub
substrat
concentr
use
current
studi
report
km
valu
respect
transport
accumul
time
transport
min
pitavastatin
min
transport
min
min
linear
uptak
rang
publish
previous
linear
uptak
rang
pitavastatin
determin
current
studi
perform
uptak
assay
cell
rins
prewarm
hbss
buffer
ph
three
time
incub
hbss
buffer
contain
min
min
pitavastatin
min
absenc
presenc
bortezomib
rifampicin
bromosulfophthalein
bsp
indic
figur
legend
rifampicin
bromosulfophthalein
potent
oatp
inhibitor
serv
posit
control
end
coincub
buffer
aspir
rapidli
cell
rins
icecold
hbss
three
time
lyse
tritonx
vv
dpb
aliquot
lysat
subject
liquid
scintil
count
scintil
counter
beckman
coulter
brea
ca
substrat
accumul
normal
protein
concentr
determin
bca
assay
pierc
chemic
rockford
il
correct
nonspecif
bind
substrat
subtract
accumul
valu
observ
perform
assay
nonoverlaid
polyllysin
coat
blank
plate
uptak
studi
stabl
cell
line
overlaid
blank
plate
human
sch
studi
determin
longlast
inhibitori
effect
bortezomib
transport
cell
preincub
vehicl
control
bortezomib
nm
h
end
preincub
cultur
medium
aspir
cell
wash
three
time
fresh
cultur
media
incub
fresh
cultur
media
without
bortezomib
indic
time
h
determin
effect
bortezomib
transport
kinet
paramet
maxim
transport
veloc
vmax
affin
constant
km
accumul
min
determin
cell
pretreat
bortezomib
nm
h
vehicl
control
vmax
km
valu
transport
estim
fit
equat
data
use
graphpad
prism
graphpad
softwar
la
jolla
ca
usa
v
transport
veloc
concentr
experi
conduct
similarli
publish
previous
slight
modif
step
conduct
ice
icecold
buffer
cell
seed
plate
densiti
x
cell
per
well
cultur
h
treat
bortezomib
nm
vehicl
control
cultur
medium
h
end
treatment
cell
incub
dpb
calcium
magnesium
contain
mgml
sulfonhsssbiotin
pierc
chemic
rockford
il
h
subsequ
cell
wash
three
time
icecold
dpb
calcium
magnesium
contain
mm
glycin
cell
lyse
lysi
buffer
contain
mm
tri
ph
mm
mm
edta
sd
proteas
inhibitor
cocktail
sonic
supernat
protein
incub
neutravidin
bead
pierc
rockford
il
overnight
gentl
rock
wash
five
time
icecold
lysi
buffer
bead
incub
laemmli
buffer
h
room
temperatur
elut
protein
supernat
resolv
sdspage
biorad
laboratori
inc
hercul
ca
usa
subsequ
immunoblot
dilut
nakatpas
dilut
abcam
cambridg
usa
antibodi
nakatpas
use
load
control
surfac
protein
level
blot
also
probe
gapdh
antibodi
dilut
santa
cruz
dalla
tx
usa
determin
whether
surfac
fraction
intracellular
protein
contamin
similar
previous
publish
incub
respect
secondari
antibodi
irdy
goat
antirabbit
irdy
goat
antimous
antibodi
immunoblot
imag
captur
satur
use
odyssey
clx
imag
system
licor
biotechnolog
lincoln
ne
accord
manufactur
instruct
densitometri
conduct
use
imag
studio
softwar
licor
biotechnolog
lincoln
ne
usa
experi
conduct
similar
publish
previous
treatment
bortezomib
vehicl
control
cell
cultur
media
assay
lactat
dehydrogenas
ldh
activ
cytotox
detect
kit
roch
diagnost
gmbh
mannheim
germani
accord
manufactur
instruct
tritonx
treat
nontreat
cell
serv
cytotox
posit
control
neg
control
respect
indic
figur
legend
fold
chang
associ
standard
error
se
estim
linear
mix
effect
model
fix
effect
treatment
time
group
random
effect
experi
date
hepatocyt
donor
allow
treatment
timegroupspecif
variat
similar
publish
previous
case
multipl
comparison
pvalu
adjust
base
bonferroni
method
within
linear
mix
effect
model
twosid
pvalu
defin
statist
signific
sa
softwar
version
cari
nc
use
statist
analys
determin
whether
could
modifi
ubiquitin
coimmunoprecipit
ip
flagtag
hatag
ubiquitin
haub
perform
cell
transient
transfect
vector
express
either
alon
combin
haubiquitin
similar
publish
previous
ip
ha
antibodi
immunoblot
ib
flag
antibodi
haubiquitinconjug
fig
lane
fig
lane
readili
detect
haub
coexpress
respect
similarli
ip
flag
antibodi
immunoblot
ha
antibodi
haub
conjug
fig
lane
fig
lane
readili
detect
haub
coexpress
respect
confirm
success
immunoprecipit
ha
flag
membran
strip
reprob
flag
ha
antibodi
respect
fig
strip
ha
flag
signal
specif
detect
haub
cell
ip
ha
flag
respect
vector
controltransfect
cell
express
haub
also
confirm
whole
cell
lysat
immunoblot
ha
flag
antibodi
load
control
fig
whole
cell
lysat
determin
effect
bortezomib
treatment
level
ubiquitinconjug
sinc
customgener
antibodi
valid
immunoprecipit
newli
establish
stabl
cell
line
use
purpos
flagtag
protein
readili
immunoprecipit
use
flag
antibodi
shown
fig
immunoblot
fig
flag
antibodi
fig
specif
detect
express
stabl
cell
line
neg
control
cell
line
accumul
min
cell
fold
higher
neg
control
cell
fig
protein
ubiquitinconjug
determin
via
immunoprecipit
flag
antibodi
follow
immunoblot
ubiquitin
antibodi
bortezomib
treatment
nm
h
total
ubiquitinconjug
protein
markedli
increas
fig
right
panel
cell
fig
right
panel
respect
compar
vehicl
control
treatment
suggest
effici
proteasom
inhibit
bortezomib
treatment
compar
vehicl
control
treatment
ubiquitinconjug
protein
detect
bortezomibtr
fig
left
panel
cell
fig
left
panel
respect
total
protein
level
fig
middl
panel
fig
middl
panel
bortezomibtr
cell
fold
vehicl
control
treatment
similarli
stabl
cell
line
bortezomib
treatment
nm
h
affect
protein
level
respect
fig
treatment
bortezomib
nm
h
also
effici
inhibit
proteasom
activ
cell
indic
markedli
increas
ubiquitinconjug
protein
fig
effect
bortezomib
treatment
total
protein
level
endogen
determin
human
sch
pretreat
bortezomib
h
nm
protein
level
fold
vehicl
control
treatment
protein
level
fold
vehicl
control
treatment
fig
total
ubiquitinconjug
protein
markedli
increas
bortezomib
treatment
nm
h
human
sch
fig
confirm
effici
inhibit
proteasom
activ
bortezomib
treatment
repres
imag
immunoblot
overlaid
molecular
weight
marker
shown
supplementari
result
fig
similar
observ
whole
cell
lysat
transporterexpress
stabl
cell
line
fig
middl
panel
follow
bortezomib
treatment
higher
molecular
weight
band
appear
human
sch
whole
cell
lysat
fig
molecular
weight
observ
human
sch
fig
fig
similar
describ
previous
human
hepatocyt
human
liver
tissu
also
similar
stabl
cell
line
fig
middl
panel
fig
right
panel
molecular
weight
human
sch
approxim
kd
kd
kd
molecular
weight
describ
previous
primari
human
hepatocyt
human
basolater
membran
human
liver
tissu
kd
molecular
weight
band
human
sch
fig
fig
similar
size
transporterexpress
stabl
cell
line
fig
middl
panel
previous
report
total
protein
level
increas
stabl
cell
line
human
sch
treatment
lysosom
inhibitor
chloroquin
current
studi
effect
chloroquin
treatment
total
protein
level
determin
stabl
cell
line
human
sch
treatment
chloroquin
h
increas
protein
level
mean
sd
n
fig
mean
sd
n
donor
fig
fold
vehicl
control
cell
human
sch
respect
unbound
maximum
plasma
concentr
cmax
bortezomib
intraven
administr
rang
nm
current
studi
determin
effect
bortezomib
transport
variou
concentr
includ
clinic
relev
concentr
nm
specif
substrat
pitavastatin
dual
substrat
effect
bortezomib
transport
cell
determin
use
three
substrat
pitavastatin
human
sch
use
probe
substrat
shown
fig
coincub
posit
control
rifampicin
significantli
decreas
accumul
min
fold
control
bonferroniadjust
p
without
bortezomib
pretreat
bortezomib
nm
affect
accumul
min
bonferroniadjust
pvalu
fig
howev
pretreat
bortezomib
nm
h
accumul
significantli
decreas
rang
fold
control
fig
human
sch
pretreat
bortezomib
nm
h
accumul
min
significantli
decreas
fold
control
respect
fig
uptak
pitavastatin
linear
least
sec
fig
oneminut
incub
time
period
use
subsequ
pitavastatin
accumul
assay
accumul
pitavastatin
fig
fig
bortezomibpretr
cell
nm
h
significantli
differ
cell
pretreat
vehicl
control
determin
whether
inhibitori
effect
bortezomib
pretreat
accumul
revers
similar
trend
shown
fig
bortezomib
pretreat
nm
h
significantli
decreas
accumul
fold
vehicl
control
pretreat
fig
h
h
cell
cultur
bortezomibfre
media
follow
initi
pretreat
bortezomib
nm
h
vehicl
control
accumul
bortezomibpretr
cell
fig
grey
bar
still
significantli
lower
vehicl
control
ctl
pretreat
cell
fig
black
bar
fold
ctl
respect
p
vs
ctl
h
cell
cultur
bortezomibfre
media
signific
differ
accumul
bortezomibpretr
cell
compar
ctl
fig
cell
pretreat
bortezomib
nm
vehicl
control
h
shown
fig
bortezomib
pretreat
nm
h
significantli
decreas
maxim
transport
veloc
vmax
valu
transport
compar
vehicl
control
treatment
vs
pmolmg
proteinmin
p
without
affect
km
valu
vs
mean
sd
n
surfac
biotinyl
assay
conduct
determin
effect
bortezomib
pretreat
nm
h
cell
surfac
protein
level
cell
shown
fig
surfac
protein
level
bortezomibtr
cell
normal
nakatpas
fold
control
mean
sd
n
total
protein
level
bortezomibtr
cell
fold
control
mean
sd
n
gapdh
detect
whole
cell
lysat
cell
surfac
fraction
suggest
surfac
protein
fraction
contamin
intracellular
protein
pitavastatin
sensit
substrat
use
studi
inhibitori
effect
toward
use
current
studi
probe
substrat
determin
effect
bortezomib
transport
cell
pitavastatin
also
use
clinic
relev
oatp
drug
substrat
human
sch
cell
coincub
posit
control
rifampicin
bortezomib
nm
significantli
decreas
accumul
pitavastatin
min
fig
min
fig
pretreat
bortezomib
nm
h
significantli
affect
accumul
pitavastatin
min
fig
min
fig
human
sch
coincub
posit
control
bromosulfophthalein
bsp
significantli
decreas
pitavastatin
accumul
fold
control
fig
pretreat
bortezomib
nm
fig
significantli
affect
pitavastatin
accumul
min
effect
pretreat
proteasom
inhibitor
epoxomicin
carfilzomib
transport
determin
cell
respect
carfilzomib
secondgener
proteasom
inhibitor
drug
unbound
cmax
nm
clinic
relev
concentr
nm
use
carfilzomib
treatment
current
studi
pretreat
epoxomicin
nm
carfilzomib
nm
h
significantli
decreas
accumul
fold
control
respect
p
vs
control
fig
effici
inhibit
proteasom
activ
current
treatment
condit
confirm
immunoblot
ubiquitin
total
ubiquitinconjug
protein
markedli
increas
cell
treat
proteasom
inhibitor
fig
consist
effici
block
protein
degrad
via
ubiquitin
proteasom
system
similar
observ
previous
pretreat
epoxomicin
nm
carfilzomib
nm
h
significantli
affect
transport
min
cell
fig
ldh
assay
reveal
neglig
cytotox
stabl
cell
line
human
sch
treat
bortezomib
nm
h
fig
mediat
hepat
uptak
divers
array
clinic
import
drug
therefor
understand
regul
transport
function
especi
commonli
administ
therapeut
drug
signific
clinic
relev
predict
potenti
oatpmedi
ddi
current
studi
determin
ubiquitin
modif
effect
proteasom
inhibitor
transport
order
determin
ubiquitin
first
examin
whether
conjug
haubiquitin
shown
fig
lane
b
haubconjug
flagtag
protein
observ
cell
haub
coexpress
result
demonstr
first
time
ubiquitinmodifi
flag
immunoblot
nonboil
whole
cell
lysat
detect
major
molecular
weight
kd
kd
respect
lane
fig
molecular
weight
compar
previous
publish
molecular
weight
cell
respect
haubiquitinconjug
protein
lane
fig
appear
molecular
weight
higher
regular
molecular
weight
kd
kd
ubiquitin
often
increas
molecular
weight
target
protein
report
protein
higher
regular
molecular
weight
haubiquitinconjug
protein
lane
fig
may
attribut
ubiquitinmodif
transport
protein
higher
molecular
weight
band
kd
observ
flag
immunoblot
flag
immunoprecipit
cell
transient
express
andor
fig
lane
sever
factor
may
involv
appear
higher
molecular
weight
band
mention
first
immunoprecipit
immunocomplex
elut
protein
ag
resin
boil
per
routin
method
accord
manufactur
instruct
well
document
membran
protein
tend
form
higher
molecular
weight
aggreg
boil
observ
similar
phenomenon
shown
supplement
result
fig
higher
molecular
weight
band
kd
whole
cell
lysat
sampl
promin
boil
band
minim
without
boil
recent
report
abl
form
homooligom
report
absenc
crosslink
agent
elut
immunoprecipit
without
boil
major
molecular
weight
kd
monom
presenc
crosslink
agent
homooligom
detect
higher
molecular
weight
kd
report
togeth
result
shown
fig
suggest
observ
higher
molecular
weight
band
kd
immunoprecipit
sampl
fig
lane
might
relat
protein
aggreg
oligomer
boil
second
previou
report
treatment
tunicamycin
inhibitor
protein
nlink
glycosyl
markedli
reduc
amount
high
molecular
weight
band
thu
posttransl
modif
glycosyl
may
also
involv
format
high
molecular
weight
band
observ
current
studi
fig
lane
ubiquitin
proteasom
system
involv
degrad
cytosol
protein
also
degrad
plasma
membran
protein
includ
transport
protein
pgp
sodium
taurochol
cotransport
polypeptid
ntcp
apic
sodiumdepend
bile
acid
transport
asbt
base
find
conjug
haubiquitin
fig
assess
potenti
involv
ubiquitinproteasom
system
degrad
bortezomib
treatment
nm
h
condit
report
current
manuscript
effici
block
proteasom
activ
indic
mark
increas
total
ubiquitinconjug
protein
bortezomib
treatment
fig
right
panel
fig
bortezomib
treatment
increas
amount
endogen
fig
left
panel
howev
obviou
increas
total
protein
level
transporteroverexpress
cell
either
regular
molecular
weight
higher
molecular
weight
posit
due
potenti
ubiquitin
fig
middl
panel
bortezomib
treatment
affect
total
protein
level
human
sch
fig
stabl
cell
line
express
untag
fig
data
support
ubiquitinproteasom
may
major
degrad
pathway
current
condit
previous
report
lysosom
involv
degrad
current
studi
found
treatment
lysosom
inhibitor
chloroquin
markedli
increas
total
protein
level
stabl
cell
line
fig
also
human
sch
fig
suggest
lysosom
also
involv
degrad
taken
togeth
data
suggest
compar
lysosom
pathway
ubiquitinproteasom
system
may
play
less
import
role
degrad
least
current
condit
ubiquitin
also
determin
transporteroverexpress
cell
fig
ubiquitin
endogen
effect
proteasom
inhibitor
ubiquitin
endogen
warrant
character
primari
human
hepatocyt
use
valid
antibodi
specif
immunoprecipit
respect
treatment
proteasom
inhibitor
associ
alter
function
transport
protein
exampl
proteasom
inhibit
decreas
serotonin
transport
sert
mediat
serotonin
uptak
efflux
function
pglycoprotein
pgp
current
studi
determin
effect
proteasom
inhibitor
transport
bortezomib
competit
inhibitor
least
concentr
nm
fig
fig
howev
pretreat
bortezomib
nm
h
significantli
decreas
accumul
stabl
cell
line
human
sch
fig
decreas
transport
induc
bortezomib
pretreat
nm
h
last
least
h
cultur
bortezomibfre
media
fig
howev
longer
evid
cultur
cell
h
bortezomibfre
media
fig
treatment
proteasom
inhibitor
epoxomicin
carfilzomib
also
significantli
decreas
transport
fig
share
varieti
common
substrat
statin
howev
substrat
tend
transport
specif
interestingli
inhibitori
effect
bortezomib
pretreat
appear
specif
transport
fig
bortezomib
pretreat
affect
transport
pitavastatin
mediat
either
fig
fig
although
pitavastatin
substrat
multipl
hepat
oatp
includ
play
primari
role
hepat
uptak
pitavastatin
lack
inhibitori
effect
bortezomib
pretreat
pitavastatin
accumul
mediat
fig
fig
consist
find
pretreat
bortezomib
affect
pitavastatin
accumul
human
sch
fig
current
mechan
bortezomib
pretreat
reduc
transport
substratedepend
manner
remain
unknown
consid
pretreat
effect
associ
substrat
dual
substrat
pitavastatin
specul
bortezomib
pretreat
may
affect
conform
bind
site
specif
associ
transport
effort
elucid
potenti
mechan
underli
decreas
transport
bortezomib
treatment
determin
effect
bortezomib
transport
kinet
bortezomib
pretreat
nm
h
markedli
decreas
vmax
valu
transport
without
appar
affect
km
valu
transport
fig
suggest
bortezomib
pretreat
mainli
affect
capac
transport
substrat
affin
transport
decreas
vmax
valu
transport
protein
pretreat
report
associ
reduc
membran
level
transport
protein
studi
like
associ
decreas
turnov
rate
transport
alter
surfac
level
transport
protein
current
studi
obviou
chang
surfac
level
observ
bortezomib
treatment
nm
h
fig
suggest
decreas
vmax
transport
bortezomib
treatment
associ
appar
chang
surfac
level
exact
mechan
underli
bortezomib
pretreat
effect
transport
warrant
character
futur
conclus
present
studi
first
time
report
ubiquitinmodifi
pretreat
bortezomib
result
moder
reduct
transport
substratedepend
manner
affect
transport
taken
togeth
data
support
bortezomib
low
potenti
caus
oatpmedi
clinic
ddi
